# EDGAR Filing Document

**Accession Number:** 0001833214
**File Stem:** 0001193125-25-335267
**Filing Date:** 2025-12
**Character Count:** 7071
**Document Hash:** 68996853738257fd70c57b96c14587a7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-335267.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001193125-25-335267

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20251229

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SAB Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001833214
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 853899721
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39871
- **FILM NUMBER:** 251609039

**BUSINESS ADDRESS:**
- **STREET 1:** 777 W 41ST ST
- **STREET 2:** SUITE 401
- **CITY:** MIAMI BEACH
- **STATE:** FL
- **ZIP:** 33140
- **BUSINESS PHONE:** 305-845-2813

**MAIL ADDRESS:**
- **STREET 1:** 777 W 41ST ST
- **STREET 2:** SUITE 401
- **CITY:** MIAMI BEACH
- **STATE:** FL
- **ZIP:** 33140

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Big Cypress Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201120

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** December 29, 2025<br>

------

SAB BIOTHERAPEUTICS, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39871 | 85-3899721 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 777 W 41st St<br>Suite 401 |  |  |
| Miami Beach**,** Florida |  | 33140 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 305 845-2813<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common stock, $0.0001 par value per share | SABS | The Nasdaq Stock Market LLC |
| Warrants, each exercisable for one share of Common Stock | SABSW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 8.01 Other Events.
*Establishment of "At the Market Offering" Program*

On December 29, 2025, SAB Biotherapeutics, Inc. (the "Company") entered into a Sales Agreement (the "Agreement") with UBS Securities LLC (the "Agent") with respect to an at-the-market offering program under which the Company may offer and sell from time to time through or to the Agent, as sales agent or principal, the Company's common stock, par value $0.0001 per share, having an aggregate offering price of up to $75,000,000 (the "Placement Shares"). The Placement Shares will be registered under the Securities Act of 1933, as amended (the "Securities Act"), and will be offered and sold pursuant to a shelf registration statement on Form S-3. The Company intends to use the net proceeds from the offering, if any, to support pipeline development and for general corporate and working capital purposes.

The Company is not obligated to sell any Placement Shares pursuant to the Agreement. Subject to the terms and conditions of the Agreement, the Agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of the Nasdaq Stock Market LLC ("Nasdaq"), to sell the Placement Shares from time to time based upon the Company's instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose. Sales of the Placement Shares, if any, will be made on Nasdaq at market prices by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) of the Securities Act. The Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to the Agreement, an amount up to 3% of the aggregate gross proceeds from each sale of Placement Shares.

The offering of the Placement Shares pursuant to the Agreement will terminate upon the termination of the Agreement as permitted therein. The Agreement may be terminated at any time by either party upon ten days' prior notice.

*Termination of Prior "At the Market Offering" Program*

Effective December 17, 2025, the Company terminated the its previous at-the-market program of shares of common stock for an amount up to $20 million, pursuant to that certain Sales Agreement, between the Company and Cantor Fitzgerald & Co. ("Cantor"), dated January 26, 2024 (the "Cantor ATM"), conducted pursuant to the Company's prospectus supplement filed with the SEC as part of the Registration Statement on Form S-3 (File No. 333-271768) on January 26, 2024 (the "Prior Prospectus Supplement"). Cantor waived any restriction under the Cantor ATM that would have restricted the Company from effecting an "at the market offering" within 60 days from the above-referenced termination. No further offerings or sales of common stock will be conducted under the Cantor ATM or the Prior Prospectus Supplement. There are no costs or payments associated with the early termination of the Cantor ATM.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | SAB Biotherapeutics, Inc. |
| Date: | December 29, 2025 | By:  | */s/ Samuel J. Reich* |
|  |  |  | Samuel J. Reich<br>Chief Executive Officer |

---

------